Merck & Co., Inc. $MRK Shares Sold by Commonwealth Financial Services LLC

Commonwealth Financial Services LLC trimmed its position in shares of Merck & Co., Inc. (NYSE:MRK) by 65.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,908 shares of the company’s stock after selling 5,407 shares during the period. Commonwealth Financial Services LLC’s holdings in Merck & Co., Inc. were worth $423,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently bought and sold shares of MRK. BlackRock Inc. increased its stake in shares of Merck & Co., Inc. by 0.5% during the 2nd quarter. BlackRock Inc. now owns 226,999,837 shares of the company’s stock worth $29,169,479,000 after purchasing an additional 1,073,507 shares during the last quarter. State Street Corp raised its stake in shares of Merck & Co., Inc. by 0.9% in the 2nd quarter. State Street Corp now owns 120,413,256 shares of the company’s stock valued at $15,573,754,000 after acquiring an additional 1,087,583 shares in the last quarter. Wellington Management Group LLP lifted its holdings in Merck & Co., Inc. by 2.3% in the 2nd quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company’s stock worth $11,083,033,000 after purchasing an additional 1,934,312 shares during the last quarter. Bank of America Corp DE lifted its holdings in Merck & Co., Inc. by 10.5% in the 1st quarter. Bank of America Corp DE now owns 30,774,221 shares of the company’s stock worth $3,701,831,000 after purchasing an additional 2,919,780 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in Merck & Co., Inc. by 23.8% during the first quarter. Dimensional Fund Advisors LP now owns 15,456,039 shares of the company’s stock valued at $1,858,938,000 after purchasing an additional 2,969,856 shares during the last quarter. 76.07% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have weighed in on MRK shares. TD Cowen boosted their target price on shares of Merck & Co., Inc. from $137.00 to $155.00 and gave the stock a “hold” rating in a research report on Wednesday, September 23rd. Argus increased their target price on shares of Merck & Co., Inc. from $145.00 to $170.00 and gave the company a “buy” rating in a research note on Tuesday, August 25th. Wells Fargo & Company lifted their price target on shares of Merck & Co., Inc. from $150.00 to $170.00 and gave the stock an “overweight” rating in a research note on Friday, September 4th. Bank of America raised their price objective on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. Finally, The Goldman Sachs Group upped their price objective on Merck & Co., Inc. from $140.00 to $160.00 and gave the company a “buy” rating in a research note on Friday, August 21st. Seventeen investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $151.92.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Investors are evaluating Merck & Co.’s Phase 3 melanoma results, which could strengthen the company’s oncology pipeline and support the long-term outlook for its cancer-drug franchise. The market’s reaction to the data is the most relevant near-term catalyst for MRK. How Investors Are Reacting To Merck Phase 3 Melanoma Results
• Positive Sentiment: Merck’s investment case continues to include a reliable dividend, strong global pharmaceutical operations and Keytruda’s leading position in oncology. The company also raised its 2026 sales outlook in its latest reported quarter, providing some support for the recovery thesis. Merck’s 2.4% Dividend Yield
• Neutral Sentiment: Articles comparing Merck with Amgen frame MRK as an income-oriented stock whose future returns depend on dividend growth, sales execution and replacing revenue as major products mature. This is a longer-term valuation consideration rather than a direct trading catalyst. Merck vs. Amgen Dividend Comparison
• Neutral Sentiment: Merck KGaA agreed to acquire Silence Therapeutics for $20 per American depositary share, a 130% premium. The deal drove SLN sharply higher but does not represent an acquisition by Merck & Co. and should not be treated as an MRK-specific catalyst. Silence Therapeutics Gets Premium Offer From Merck KGaA
• Negative Sentiment: Exchange-traded funds were reported as net sellers of MRK on October 16, suggesting some passive or institutional selling pressure. The flow is a short-term technical headwind, although it does not by itself change Merck’s fundamentals. ETFs Are Net Sellers of Merck

Merck & Co., Inc. Price Performance

Shares of MRK stock traded up $4.35 during trading hours on Tuesday, reaching $147.98. 3,241,876 shares of the company were exchanged, compared to its average volume of 10,607,299. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10. The stock’s fifty day moving average is $145.86 and its two-hundred day moving average is $129.48. Merck & Co., Inc. has a fifty-two week low of $82.01 and a fifty-two week high of $156.92. The company has a market cap of $365.10 billion, a price-to-earnings ratio of 118.35, a P/E/G ratio of 6.74 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%. The business had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. During the same quarter in the prior year, the firm posted $2.13 earnings per share. The firm’s revenue for the quarter was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Sell-side analysts forecast that Merck & Co., Inc. will post 2.66 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th were paid a $0.85 dividend. The ex-dividend date of this dividend was Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.3%. Merck & Co., Inc.’s dividend payout ratio is 272.00%.

Insider Transactions at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP Chirfi Guindo sold 10,000 shares of the stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $135.00, for a total value of $1,350,000.00. Following the sale, the executive vice president directly owned 36,613 shares in the company, valued at approximately $4,942,755. This trade represents a 21.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Jennifer Zachary sold 80,315 shares of the firm’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total value of $10,718,839.90. Following the sale, the executive vice president directly owned 45,509 shares in the company, valued at $6,073,631.14. The trade was a 63.83% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 228,238 shares of company stock valued at $29,977,783. Corporate insiders own 0.17% of the company’s stock.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.